Fig. 7
From: Prognostic, oncogenic roles, and pharmacogenomic features of AMD1 in hepatocellular carcinoma
The “Oncopredict” R package was used to calculate the predicted 50% inhibitory concentration (IC50) based on the Genomics of Drug Sensitivity in Cancer drug data source and the training cohort gene expression profile data, boxplot to show differences of predicted drug IC50 value between risk score groups. (A) Axitini. (B) Cisplatin. (C) Cytarabine. (D) Dasatinib. (E) Fludarabine. (F) Gemcitabine. (G) Gefitinib. (H) Oxaliplatin. (I) Sorafenib. Comparisons between two groups were assessed using the Wilcoxon test